Metformin
Glucophage
Metformin (Glucophage) is a longevity & bioregulators research compound. A biguanide that inhibits mitochondrial complex I, activates AMPK and suppresses hepatic gluconeogenesis. The geroscience interest comes from cohort observations and from the AMPK/mTOR axis; the TAME trial was designed to test the ageing claim directly.
Metformin quick facts
| Reported research dose | 500mg-2000mg |
| Route | Oral |
| Frequency | 1-2x Daily |
| Half-life | ~6 hrs (IR) / ~17 hrs (XR) |
| Forms | Oral |
| Evidence level | Extensive human data (diabetes); ageing claim unproven |
Established, cheap and genuinely good for its actual indication. Two honest caveats for the longevity crowd: it DEPLETES B12 — check it annually and check MMA if borderline, because this gets missed for years and presents as fatigue and neuropathy. And there's reasonable evidence it BLUNTS resistance-training adaptations and the aerobic response to exercise, which is an awkward trade if training is the rest of your plan. Prescription only.
How Metformin works
A biguanide that inhibits mitochondrial complex I, activates AMPK and suppresses hepatic gluconeogenesis. The geroscience interest comes from cohort observations and from the AMPK/mTOR axis; the TAME trial was designed to test the ageing claim directly.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Metformin
Buy Metformin at AlgoRx →The evidence for Metformin
Graded by what exists behind each claim.
✅ Clinically validated
- One of the most-studied drugs in medicine, first-line for type 2 diabetes worldwide for over sixty years. UKPDS showed reduced diabetes-related endpoints and all-cause mortality in overweight diabetics, and the Diabetes Prevention Program showed it reduced progression from prediabetes to diabetes by 31% — though lifestyle intervention beat it at 58%.
- The longevity use is not proven. The TAME trial, designed specifically to test metformin as an ageing intervention in non-diabetics, has struggled for funding and has not reported. The observational claim that diabetics on metformin outlive non-diabetics has been challenged on methodological grounds and is not settled.
- One finding worth knowing before stacking it with training: a randomized trial in older adults found metformin *blunted* the gains in muscle mass from resistance exercise.
📊 Correlative data
- Enormous real-world record. GI effects are the common limitation and largely dose- and formulation-dependent — extended-release is substantially better tolerated. Long-term use depletes B12 and periodic testing is a reasonable habit rather than a precaution.
- Lactic acidosis is the feared risk and is genuinely rare, concentrated in people with significant renal impairment.
🧪 Theoretical / extrapolated
- Inhibits mitochondrial complex I, raising the AMP:ATP ratio and activating AMPK — which suppresses hepatic gluconeogenesis, the main source of its glucose-lowering effect. It also acts on the gut microbiome and increases GDF15, which may explain part of the appetite effect.
- AMPK activation opposes mTOR, which is the mechanistic basis for both the longevity interest and the blunted training adaptation. They are the same mechanism read two ways — suppressing growth signaling is protective against age-related damage and directly counterproductive when you are trying to build muscle.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Metformin actually does
Metformin is a positively charged molecule that cannot cross a membrane on its own, and every real feature of the drug follows from that one physical fact. At physiological pH the biguanide is a cation. It does not diffuse through lipid; it has to be carried. The carriers are organic cation transporters — OCT1 in the hepatocyte, OCT2 in the renal tubule, PMAT and OCT3 in the gut wall — and the tissues that express them are the only tissues the drug reaches in quantity Foretz 2023.
Consequence one: it concentrates where the transporter is, which is not where people think. The intestinal wall sees concentrations far above plasma, and the hepatocyte sees more than the rest of the body because portal blood delivers it there first. Skeletal muscle, which has little OCT1, sees comparatively little. A mechanism written as though metformin acted on muscle is a mechanism written for a drug that cannot get in.
Consequence two: the target is inside the mitochondrion, and the classical account has recently gained a second complex. The cation accumulates in the mitochondrial matrix, driven by the membrane potential, and inhibits complex I of the respiratory chain. In 2022 a study reported that metformin, phenformin and galegine also inhibit complex IV activity and reduce glycerol-derived gluconeogenesis LaMoia 2022. That is a second target on the same chain, and it matters because gluconeogenesis from glycerol and from lactate use different redox routes — inhibiting two complexes rather than one changes which substrates the liver can still make glucose from.
Consequence three: the AMPK story is real but secondary. Respiratory inhibition raises the cellular AMP:ATP ratio, which activates AMP-activated protein kinase. AMPK suppresses lipogenesis and switches the cell toward catabolism. But gluconeogenesis is suppressed by metformin in AMPK-null hepatocytes as well, so AMPK is a consequence of the energetic hit rather than the mechanism of the glucose effect Foretz 2023. The energy-charge change is upstream of the kinase everybody names.
Consequence four, and the newest: a large part of the effect may never leave the gut. A 2024 review sets out the gastrointestinal mechanisms specifically — effects on enterocyte glucose handling, on bile-acid recirculation, on GLP-1 secretion and on the microbiota Cheng 2024. This is the cleanest explanation for two facts nobody else accounts for: that delayed-release formulations designed to stay in the intestine still lower glucose, and that the commonest adverse effect of the drug is in the organ it never leaves.
Cell, rodent, human — and where it stops
Step one, molecular: cell and mitochondrial work. Complex I inhibition, the complex IV finding LaMoia 2022 and the transporter dependence Foretz 2023 are established in isolated systems where the concentration is set by the experimenter. The chronic obstacle to reading this literature is that many cell studies use millimolar metformin and human plasma is micromolar — which is why the intestinal wall, where local concentration really is high, is the compartment where in-vitro concentrations and reality overlap Cheng 2024.
Step two, humans, randomized, and followed for twenty-one years. The Diabetes Prevention Program randomized adults with prediabetes to intensive lifestyle intervention, metformin or placebo. Across 3,195 participants followed for 21 years, diabetes incidence was reduced in the original lifestyle group (hazard ratio 0.76, 95% CI 0.68–0.85) and in the original metformin group (hazard ratio 0.83, 95% CI 0.74–0.93) Knowler 2025. This is one of the longest randomized follow-ups of any drug on this site, and the two hazard ratios sitting side by side are the honest comparison: lifestyle beat the drug, and the drug worked.
Step three, the endpoint people actually want. The same cohort was analyzed for mortality Lee 2021. Diabetes incidence is a diagnosis; mortality is an outcome; and a drug that changes the first does not automatically change the second. That the analysis had to be done separately, in a cohort this large and this long, is itself the answer to how easily a surrogate transfers.
Step four, the geroscience extrapolation, clearly labeled as extrapolation. The interest in metformin as a longevity drug rests on the mechanism above — a mild, chronic, transporter-limited restriction of oxidative phosphorylation in liver and gut, which is the same kind of signal that dietary restriction produces — plus observational cohorts. It does not rest on a randomized lifespan trial in humans, because none exists. The DPP follow-up is the closest thing there is, and its endpoint is diabetes incidence, not aging Knowler 2025.
Where the chain breaks. (1) Every DPP participant had prediabetes; the hazard ratios do not transfer to a metabolically healthy person, and the group in which metformin has been most studied is the group least like the reader who wants it for longevity. (2) The OCT-transporter dependence means genotype changes exposure, and no trial above was stratified by it. (3) The exercise interaction — whether metformin blunts adaptation to training by damping the same energetic signal training depends on — is an active argument with mixed results and no definitive trial. (4) Gut mechanisms Cheng 2024 and hepatic mechanisms are usually measured in different studies, so nobody has apportioned the human effect between them.
What would have to be true, and how you would know it was not
Three predictions. The third is the one that cuts against long-term use and it is measured with a single test.
1. If the drug is being absorbed and the transporters are working, the glucose markers move within a quarter. HbA1c and fasting insulin at baseline and 12 weeks. HbA1c reflects roughly three months of red-cell exposure, so a 6-week check is uninterpretable and a 12-week check is not. If neither moves in somebody with a raised baseline, the plausible explanations are under-dosing, an OCT1 reduced-function genotype, or a formulation that is passing through.
2. The kidney is the gate on the whole drug, and it is a number. Metformin is cleared renally by OCT2 and MATE transporters, so falling kidney function raises exposure directly. A CMP with creatinine, and an eGFR calculated from it, at baseline and annually is the measurement that decides whether the drug is still appropriate. Cystatin C is the better estimate in anyone with unusual muscle mass, where creatinine misleads in both directions.
3. The prediction that argues against staying on it indefinitely: vitamin B12. Long-term metformin is an established cause of B12 malabsorption, and the mechanism is exactly the gut-localized action described above Cheng 2024. Vitamin B12 annually, and MMA when B12 sits in the low-normal band, because methylmalonic acid rises before serum B12 falls out of range. The failure mode is a peripheral neuropathy attributed to diabetes that was actually caused by the drug for diabetes, and the two are clinically indistinguishable without the test.
What will fool you. Gastrointestinal upset in the first fortnight is expected and usually settles; sudden new nausea, vomiting and deep breathing months into stable therapy is not the same thing and belongs in the safety section below.
What nobody has tested yet
Four experiments nobody has run.
Nobody has run a randomized aging trial in humans. Every longevity claim for metformin rests on mechanism plus observational cohorts. TAME — a trial designed with a composite age-related disease endpoint — has been discussed for a decade and the result does not exist. Until it does, this page will keep saying so.
Nobody has stratified a metformin trial by OCT1 genotype. The transporter determines hepatic exposure Foretz 2023; reduced-function variants are common; every trial above averages carriers and non-carriers. This is the single cheapest study that would improve prescribing, and it has not been done at scale.
Nobody has separated the gut effect from the liver effect in humans. A head-to-head of immediate-release against a gut-retained delayed-release formulation, matched on glucose lowering and read out with hepatic and intestinal endpoints, would apportion the mechanism Cheng 2024. The formulations exist. The trial does not.
Nobody has resolved the exercise question properly. The hypothesis is specific and falsifiable: if metformin's effect is a mild energetic restriction, and training adaptation depends on an energetic stress signal, the two should interfere. A randomized trial in older adults with mitochondrial and strength endpoints, powered for an interaction rather than a main effect, would answer it. The existing trials were not designed that way and their results disagree.
Metformin — its own safety story, not its class's
Metformin is a prescription medicine with sixty years of post-marketing data, so the generic block above is the wrong instrument. Here is what is specific to this molecule.
Lactic acidosis is the one that carries the boxed warning, and it is a mechanism rather than an idiosyncrasy. Complex I inhibition LaMoia 2022 shifts pyruvate toward lactate. In normal kidney function the excess is cleared and never appears. In acute kidney injury, decompensated heart failure, sepsis, severe liver disease or heavy alcohol use, drug accumulates and lactate clearance falls at the same time. The presenting picture is malaise, muscle aching, unusual sleepiness, abdominal pain and hyperventilation — and it is rare, and it is a medical emergency.
The practical version of that warning is the sick-day rule. The circumstances that cause it are the circumstances that cause dehydration: vomiting, diarrhea, a day of fever, an imaging study with iodinated contrast, or the run-up to surgery. Those are the days the drug is held, and it is a decision made with the prescriber, not something a page can prescribe.
B12 depletion is the slow one and it is the one people miss. It develops over years, it is asymptomatic until it is not, and it is detectable by a cheap test Cheng 2024. The monitoring is in the predictions section above because it belongs to the falsifiable part of this page, not to a warning list.
Gastrointestinal intolerance is a dose and formulation question. It is the commonest reason people abandon the drug, it reflects the intestinal concentration that also produces part of the benefit, and extended-release formulations exist specifically for it — which is why the card lists two different half-lives, roughly 6 hours immediate-release and 17 hours extended-release.
What this page will not do. Recommend a dose, or suggest taking a prescription drug for longevity on the strength of a mechanism. The DPP hazard ratios Knowler 2025 were measured in people with prediabetes under randomization, and that is the population the evidence belongs to.
Sources read for this page
- Foretz M, et al. Metformin: update on mechanisms of action and repurposing potential. Nature Reviews Endocrinology 2023 · PMID 37130947
- LaMoia TE, et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proceedings of the National Academy of Sciences 2022 · PMID 35238637
- Cheng M, et al. Understanding the action mechanisms of metformin in the gastrointestinal tract. Frontiers in Pharmacology 2024 · PMID 38617792
- Knowler WC, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes and Endocrinology 2025 · PMID 40311647
- Lee CG, et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2021 · PMID 34697033
Metformin — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- A biguanide that inhibits mitochondrial complex I, activates AMPK and suppresses hepatic gluconeogenesis. The geroscience interest comes from the AMPK/mTOR axis and from cohort observations, and the TAME trial was designed to test the ageing claim directly.
- Two predictions follow from complex I inhibition. Lactate rises because the cell shifts toward glycolysis — normally trivially, and dangerously if it cannot be cleared, which is what makes kidney function the governing variable. And the same energetic signal that mimics exercise may blunt the adaptation to it, which is the live question below.
What has actually been reported
- Gastrointestinal upset in a large minority — nausea, diarrhea, metallic taste — mostly early, mostly dose-related, and much reduced by extended-release formulations and slow titration.
- Vitamin B12 malabsorption is common with long-term use and is the most consistently under-monitored effect of the drug. It can present as a neuropathy that gets attributed to diabetes.
- Lactic acidosis is rare and is the reason for the renal threshold — essentially confined to people with significant renal impairment, acute illness, or heavy alcohol use.
- A randomized trial in older adults found metformin blunted the increase in muscle mass and the mitochondrial adaptation to resistance training. That is a real, replicated-direction finding and it matters more to this audience than to almost any other.
How to reduce the risk
Same mechanism as the prediction.
- Take B12 seriously — test it, don't assume. This is the one predictable deficiency the drug causes and it is cheap to catch.
- Hold it for illness, dehydration, surgery and contrast imaging.
- Start low, use the extended-release form, take it with food. Most people who cannot tolerate metformin were titrated too fast.
- If your plan is built on hypertrophy, consider the timing. Separating it from training blocks, or reconsidering it entirely during one, is a defensible response to the exercise-blunting data.
What it does to your bloodwork
A fact about the assay.
- B12 at baseline and annually — and MMA if B12 is low-normal, because serum B12 misses functional deficiency and that is exactly the failure mode here.
- eGFR, and cystatin C rather than creatinine if you carry significant muscle mass — creatinine-based eGFR under-reads kidney function in lifters, which is the group most likely to be told to stop unnecessarily.
- HbA1c and fasting insulin to know whether it is doing anything.
What it overlaps with
- Adds to hypoglycemia risk only in combination with insulin or a sulfonylurea — metformin alone rarely causes it.
- Iodinated contrast and any acute kidney insult are the situations where the lactic acidosis risk becomes real.
Don't run this if
- Significantly reduced kidney function — the threshold is a clinical decision and eGFR is how it is made.
- Acute illness with dehydration, sepsis or hypoxia; the days around surgery or iodinated contrast imaging.
- Heavy alcohol use.
The honest unknown
- Whether it helps or hinders a training-driven longevity strategy. The exercise-blunting finding and the geroprotection hypothesis point in opposite directions for someone whose plan is built on resistance training, and no trial has resolved which effect dominates over years. This is a genuine open question, not a hedge.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Metformin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Metformin moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Metformin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Metformin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Metformin — frequently asked questions
What is Metformin?
Metformin (Glucophage) is a longevity & bioregulators research compound. A biguanide that inhibits mitochondrial complex I, activates AMPK and suppresses hepatic gluconeogenesis. The geroscience interest comes from cohort observations and from the AMPK/mTOR axis; the TAME trial was designed to test the ageing claim directly.
Is the full Metformin protocol on this page?
The reported research dose is on this page, along with how Metformin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Metformin?
Metformin has an approximate half-life of ~6 hrs (IR) / ~17 hrs (XR), which is part of what determines how often it's dosed.
What's the evidence behind Metformin?
Current evidence level: Extensive human data (diabetes); ageing claim unproven. Metformin is offered for research purposes only and is not an approved medicine.
Metformin inside a finished plan
One arm of 4 Protocol Blueprints, free to read in full.
What Metformin is used for
Metformin appears under 4 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Metformin is the insulin-sensitivity arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.